Bottom Line Retatrutide keeps doing the thing people hoped it would do, but at a scale that keeps surprising the market
Johns EJ, Kopp UC, DiBona GF
The abdomen, including the area above the navel, is one of the recommended injection sites, provided you maintain the correct distance from anatomical landmarks
In some cases, things are more severe
These trials include more than 2,050 participants across diverse regions, and the first major results from TRANSCEND-T2D-1 are expected to be presented at the American Diabetes Association Scientific Sessions in June, then published in a peer-reviewed journal
Recommended Expanding focus for cardiologists The diabetic patient and cardiovascular outcomesIntroduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes Prof